SIRT3 inhibition promotes age-associated vascular impairment by mediating mitochondrial dysfunction and endothelial-to-mesenchymal transition.

Shiye Ke, Huijun Yang, Weifeng Lu, Lin Wu, Yuzhen Zhang, Xiaoxian Qian, Yanming Chen

Department of Endocrinology and Metabolic Diseases, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen, 518033, Guangdong Province, China; Department of Cardiology, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518033, Guangdong Province, China; Biological Laboratory of Hetao Cooperation Zone, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518033, Guangdong Province, China. · pubmed

Paper

Abstract

Vascular aging profoundly impacts on cardiovascular disease. Sirtuin 3 (SIRT3) is a key regulator of metabolic homeostasis whose expression declines with age; however, the mechanisms linking SIRT3 deficiency to age-associated vascular impairment remain unclear. Here, we investigated whether SIRT3 deficiency drives age-associated vascular impairment by inducing mitochondrial dysfunction and initiating endothelial-to-mesenchymal transition (EndMT).

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

SIRT3 deficiency drives age-associated vascular impairment by inducing mitochondrial dysfunction and endothelial-to-mesenchymal transition. This study provides mechanistic insight into a specific pathway of vascular aging, representing a standard incremental advance in the field of geroscience rather than a transformative breakthrough.

Author of this paper? Send a correction.